Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny particles in the blood may signal early vessel damage from high blood pressure

NCT ID NCT07728630

Knowledge-focused Sponsor: Josip Juraj Strossmayer University of Osijek Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study compares levels of tiny particles shed from blood vessels in people with newly diagnosed, untreated high blood pressure versus those with normal blood pressure. Researchers want to see if these particles can serve as early, non-invasive markers of blood-vessel injury. The goal is to better understand how high blood pressure damages vessels from the start and potentially improve early detection of cardiovascular risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If tiny blood-vessel particles prove to be reliable early warning signs, doctors might one day use a simple blood test to catch blood-vessel damage before it leads to heart disease.
What could go wrong
This is an early observational study, not a treatment trial. It can only show links, not cause and effect, and the findings may not lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult men and women aged 18 years and older recruited from the outpatient clinics of the University Hospital Centre Osijek, Croatia. The study will include normotensive individuals and patients with newly diagnosed, previously untreated primary hypertension. Healthy volunteers will serve as the control group.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Ability and willingness to provide written informed consent. * Normotensive individuals or individuals with newly diagnosed, previously untreated primary hypertension, classified according to the European Society of Hypertension (ESH) guidelines. * Ability to comply with all study procedures. Exclusion Criteria: * Secondary hypertension. * Previous treatment with antihypertensive medication. * History of cardiovascular disease (except newly diagnosed primary hypertension in the hypertensive group). * Diabetes mellitus. * Chronic kidney disease. * Cerebrovascular disease. * Peripheral arterial disease. * Acute or chronic inflammatory or infectious disease. * Active malignancy. * Pregnancy or breastfeeding. * Current use of oral contraceptives, hormone replacement therapy, or medications known to affect endothelial function. * Inability or unwillingness to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endothelial function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endothelial function Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Osijek

    RECRUITING

    Osijek, 31000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.